Bicara Therapeutics Inc. Common Stock BCAX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:49:34.060Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T13:05:21.723493382Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:49:33.701958+00:00
Bicara Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 12.23 | 160.2% | 24.0% | 8.25 | 594.9% | 43.1% |
| 30Δ | 11.94 | 187.2% | 23.7% | 9.06 | 508.1% | 35.3% |
| 35Δ | 11.64 | 214.1% | 23.3% | 9.86 | 421.2% | 27.6% |
| 40Δ | 11.35 | 241.1% | 23.0% | 10.32 | 379.7% | 23.6% |
| 45Δ | 11.06 | 268.1% | 22.7% | 10.70 | 347.3% | 20.4% |
| 50Δ | 10.77 | 295.1% | 22.4% | 11.08 | 314.9% | 17.2% |
| 55Δ | 10.47 | 322.0% | 22.1% | 11.47 | 282.4% | 14.0% |
| 60Δ | 10.18 | 349.0% | 21.8% | 11.85 | 250.0% | 10.7% |
| 65Δ | 12.23 | 217.6% | 7.5% | |||
| 70Δ | 13.02 | 208.9% | 5.2% | |||
| 75Δ | 14.74 | 255.7% | 4.8% | |||
| 80Δ | 16.05 | 262.1% | 3.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 12.23
- IV
- 160.2%
- B/E move
- 24.0%
- Pseudo strike
- 8.25
- IV
- 594.9%
- B/E move
- 43.1%
30Δ
- Pseudo strike
- 11.94
- IV
- 187.2%
- B/E move
- 23.7%
- Pseudo strike
- 9.06
- IV
- 508.1%
- B/E move
- 35.3%
35Δ
- Pseudo strike
- 11.64
- IV
- 214.1%
- B/E move
- 23.3%
- Pseudo strike
- 9.86
- IV
- 421.2%
- B/E move
- 27.6%
40Δ
- Pseudo strike
- 11.35
- IV
- 241.1%
- B/E move
- 23.0%
- Pseudo strike
- 10.32
- IV
- 379.7%
- B/E move
- 23.6%
45Δ
- Pseudo strike
- 11.06
- IV
- 268.1%
- B/E move
- 22.7%
- Pseudo strike
- 10.70
- IV
- 347.3%
- B/E move
- 20.4%
50Δ
- Pseudo strike
- 10.77
- IV
- 295.1%
- B/E move
- 22.4%
- Pseudo strike
- 11.08
- IV
- 314.9%
- B/E move
- 17.2%
55Δ
- Pseudo strike
- 10.47
- IV
- 322.0%
- B/E move
- 22.1%
- Pseudo strike
- 11.47
- IV
- 282.4%
- B/E move
- 14.0%
60Δ
- Pseudo strike
- 10.18
- IV
- 349.0%
- B/E move
- 21.8%
- Pseudo strike
- 11.85
- IV
- 250.0%
- B/E move
- 10.7%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.23
- IV
- 217.6%
- B/E move
- 7.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.02
- IV
- 208.9%
- B/E move
- 5.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.74
- IV
- 255.7%
- B/E move
- 4.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.05
- IV
- 262.1%
- B/E move
- 3.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 98.46% | |
| 96.58% | |
| 90.61% | |
| 117.37% | |
| 189.35% | |
| 81.75% | |
| 69.37% | |
| 71.87% | |
| 77.41% | |
| 75.43% | |
| 89.33% | |
| 76.56% | |
| 83.24% | |
| 81.87% | |
| 83.82% | |
| 84.85% | |
| 104.35% | |
| 99.91% | |
| 82.08% | |
| 83.12% | |
| 96.92% | |
| 112.19% | |
| 173.92% | |
| 84.57% | |
| 87.58% | |
| 87.44% | |
| 87.72% | |
| 90.69% | |
| 95.68% | |
| 117.35% | |
| 132.51% | |
| 144.32% | |
| 169.10% | |
| 185.86% | |
| 221.73% | |
| 100.12% | |
| 98.69% | |
| 96.64% | |
| 94.21% | |
| 101.32% | |
| 104.59% | |
| 108.60% | |
| 110.52% | |
| 209.81% | |
| 198.08% |
Biotechnology
BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is…
More →BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
More →BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in…
More →BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The…
More →BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular…
More →BMEA
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically…
More →